Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (49688)	12/18/2003 11:38:16 PM
From: wilywilly	Respond to of 57110

I glad to hear that I'm not the only one out there who got their head handed to them trying to short GERN. They have never made any money and seem like a prime shorting opp, but they are very good at printing press releases whenever anything at all happens, and for some strange reason, people bid up their stock. I've learned to stay away, too. Ouch!

To: tuck who wrote (49688)	12/19/2003 6:34:17 PM
From: Libbyt	Read Replies (1) \| Respond to of 57110

Roche is willing to make early stage deals, but I think they'd wait for more data first Thanks for your thoughts on this issue. You probably are correct with your thinking, but IMO Roche would have the ablity to make this acquisition. Roche is currently working with GERN on several diagnostic tests. From the GERN web site: "We are working with Roche Diagnostics to develop the clinical potential of our telomerase detection technology. Research data shows that an assay for telomerase is a more sensitive and specific test for bladder cancer screening than other commercially available tests. We believe that these and other data support the clinical application of telomerase assays in diagnosis, staging, monitoring and screening for bladder, cervical, prostate and other cancers." .. for the stem cell issues, they'd have to move those operations out of this country to avoid our regulations, and that doesn't seem practical to me. IMO some of the best scientists have already left this country due to the restrictions placed on stem cell research, and the restrictions on funding at several major universities. With the purchase of The Roslin Institute GERN has the ability to continue research in England where the laws on stem cell research aren't as restrictive. ~Congratulations~ again with your great Biotech Picks for 2003. I'm looking forward to seeing your new Biotech Picks for 2004!